Seqirus

Seqirus is a biopharmaceutical company and vaccine business within CSL Limited, the Australia-based biotechnology group. It was established in 2015 when CSL brought together its vaccine operations with Novartis’s influenza-vaccine business. The combination gave the business a substantial international influenza-vaccine footprint and made seasonal and pandemic influenza preparedness central to its identity. The company develops, manufactures, and supplies influenza vaccines and other vaccines. Its offerings have included cell-based and adjuvanted influenza vaccines, as well as vaccines for other infectious diseases. Product availability and names vary by country and season; vaccination programs and product approvals are determined by local regulators and public-health authorities. Seqirus serves healthcare systems and customers across multiple markets, including Australia, the United States, and the United Kingdom. Its operations are part of CSL’s global biotechnology and biopharmaceutical group, rather than an independent publicly listed company. CSL is listed in Australia. Seqirus’s role within the group is particularly associated with vaccine research, production, and preparedness for influenza and other infectious-disease threats.

Seqirus was created in 2015 as CSL consolidated its vaccine activities with the acquisition of Novartis’s influenza-vaccine business. The transaction brought together CSL’s existing vaccine operations and Novartis’s influenza portfolio in a new business focused on vaccine development and supply. CSL’s acquisition and integration established the foundation for Seqirus as an international influenza-vaccine company. The new business combined products, manufacturing assets, and expertise in influenza vaccination. It operated within CSL rather than as a separate listed company. This structure linked Seqirus’s vaccine activities to CSL’s broader biotechnology and biopharmaceutical operations, while giving the business a distinct identity in vaccine markets. Influenza vaccines became a defining part of Seqirus’s work. The company has supplied seasonal influenza vaccines and developed offerings using different manufacturing and formulation approaches, including cell-based and adjuvanted vaccines. Its products have been marketed under names including Flucelvax, Fluad, and Afluria, with product availability dependent on market-specific approvals and public-health recommendations. Seqirus’s activities also extend beyond seasonal influenza vaccines to other vaccine and infectious-disease-related work. Its international operations include major markets such as Australia, the United States, and the United Kingdom. As a part of CSL, the business contributes vaccine research, manufacturing, and supply capabilities to the parent group’s response to infectious-disease needs, including preparedness for influenza outbreaks and pandemics.

• 2015

  Seqirus established following CSL’s acquisition of Novartis’s influenza-vaccine business

A global vaccine business within CSL, with a strong emphasis on influenza vaccines, manufacturing capability, and preparedness for seasonal and pandemic influenza.

• Flucelvax

  A cell-based influenza vaccine brand.

• Fluad

  An adjuvanted influenza vaccine brand.

• Afluria

  An influenza vaccine brand.

1. 1Seqirus (global) — Wikidatawikidata.org
2. 2Seqirus official websiteseqirus.com